GRTX News and Press, Galera Therapeutics Inc. From 05/01/23

Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA)...

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announce...

2023-04-24 18:33:13 ET Summary Pivotal Phase 3 results were erroneously reported as missing both the primary and secondary endpoints causing a 70% share price drop in 2021. Phase 3 results actually hit both primary & a key secondary endpoint. The share price has not recove...

MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announce...

2023-03-08 07:48:20 ET Galera Therapeutics press release ( NASDAQ: GRTX ): Q4 GAAP EPS of -$0.58 misses by $0.06 . As of December 31, 2022, Galera had cash, cash equivalents and short-term investments of $31.6 million. Galera expects that its existing cash, cash eq...

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering MALVERN, Pa., March 08, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, I...

Bank of America upgraded micro-cap biotech Galera Therapeutics ( NASDAQ: GRTX ) to Buy from Underperform on Thursday, citing the FDA priority review the company received for its marketing application for lead asset avasopasem. Galera ( GRTX ) seek to market avasopasem manganese fo...

Galera Therapeutics ( NASDAQ: GRTX ) was trading ~16% down after the biopharmaceutical company said it is set to sell 14.32M shares and warrants to purchase up to 14.32M shares in an ~$30M registered direct offering. The offering involves a price of $2.095 per share and accompany...

MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced...

Clinical-stage biotech Galera Therapeutics ( NASDAQ: GRTX ) gained ~9% pre-market Wednesday after announcing that the FDA accepted and granted priority review for its marketing application for lead product candidate avasopasem. Filing the New Drug Application (NDA), Galera ( GRTX ...